{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T04:59:04Z","timestamp":1791176344966,"version":"4.1.0"},"reference-count":31,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2009,8]]},"DOI":"10.1097\/cad.0b013e32832b511e","type":"journal-article","created":{"date-parts":[[2009,6,30]],"date-time":"2009-06-30T03:19:54Z","timestamp":1246331994000},"page":"634-638","source":"Crossref","is-referenced-by-count":37,"title":["Prolonged survival in a patient with BRCA2 associated metastatic pancreatic cancer after exposure to camptothecin: a case report and review of literature"],"prefix":"10.1097","volume":"20","author":[{"given":"Edward","family":"James","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maeve G.","family":"Waldron-Lynch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Wasif","family":"Saif","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-13-20210203","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1136\/bmj.305.6858.855","article-title":"Risk of prostate, ovarian and endometrial cancer among relatives of women with breast cancer","volume":"305","author":"Tulinius","year":"1992","journal-title":"BMJ"},{"key":"R2-13-20210203","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1038\/ng0596-120","article-title":"Mutation analysis of the BRCA2 gene in 49 site-specific breast cancer families","volume":"13","author":"Phelan","year":"1996","journal-title":"Nat Genet"},{"key":"R3-13-20210203","first-page":"1310","article-title":"The breast cancer linkage consortium","volume":"91","year":"1999","journal-title":"J Natl Cancer Inst"},{"key":"R4-13-20210203","doi-asserted-by":"crossref","first-page":"7508","DOI":"10.1158\/1078-0432.CCR-05-1048","article-title":"In vivo therapeutic responses contingent on Fanconi anemia\/BRCA2 status of the tumor","volume":"11","author":"Van der Heijden","year":"2005","journal-title":"Clin Cancer Res"},{"key":"R5-13-20210203","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/S0002-9440(10)63329-9","article-title":"Functional defects in the fanconi anemia pathway in pancreatic cancer cells","volume":"165","author":"Van der Heijden","year":"2004","journal-title":"Am J Pathol"},{"key":"R6-13-20210203","doi-asserted-by":"crossref","first-page":"139","DOI":"10.18388\/abp.2003_3721","article-title":"Defective BRCA2 influences topoisomerase I activity in mammalian cells","volume":"50","author":"Rahden-Staro\u00f1","year":"2003","journal-title":"Acta Biochim Pol"},{"key":"R7-13-20210203","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.1200\/JCO.1997.15.6.2403","article-title":"Improvements in survival and clinical benefit with gemcitabine as first line therapy for patients with advanced pancreas cancer: a randomised trail","volume":"15","author":"Burris","year":"1997","journal-title":"J Clin Oncol"},{"key":"R8-13-20210203","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1200\/JCO.2006.07.9525","article-title":"Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group","volume":"25","author":"Moore","year":"2007","journal-title":"J Clin Oncol"},{"key":"R9-13-20210203","first-page":"83","article-title":"Optimal second line treatment options for gemcitabine refractory advanced pancreatic cancer patients. Can we establish standard of care with available data?","volume":"9","author":"Kang","year":"2008","journal-title":"JOP"},{"key":"R10-13-20210203","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1634\/theoncologist.9-1-13","article-title":"Recognition and management of hereditary breast cancer syndromes","volume":"9","author":"Thull","year":"2004","journal-title":"Oncologist"},{"key":"R11-13-20210203","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1038\/ng0396-333","article-title":"The complete BRCA2 gene mutations in chromosome 13q-linked kindreds","volume":"12","author":"Tavtigian","year":"1996","journal-title":"Nat Genet"},{"key":"R12-13-20210203","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/S0092-8674(02)00615-3","article-title":"Cancer susceptibility and the functions of BRCA1 and BRCA2","volume":"108","author":"Venkitaraman","year":"2002","journal-title":"Cell"},{"key":"R13-13-20210203","doi-asserted-by":"crossref","first-page":"13869","DOI":"10.1073\/pnas.95.23.13869","article-title":"The BRCA2 gene product functionally interacts with p53 and RAD51","volume":"95","author":"Marmorstein","year":"1998","journal-title":"Proc Natl Acad Sci USA"},{"key":"R14-13-20210203","doi-asserted-by":"crossref","first-page":"4533","DOI":"10.1128\/MCB.19.7.4633","article-title":"Interaction between the product of the breast cancer susceptibility gene BRCA2 and DSS1, a protein functionally conserved from yeast to mammals","volume":"19","author":"Marston","year":"1999","journal-title":"Mol Cell Biol"},{"key":"R15-13-20210203","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1038\/sj.onc.1204098","article-title":"Inhibition of breast and brain cancer cell growth by BCCIPalpha, an evolutionarily conserved nuclear protein that interacts with BRCA2","volume":"20","author":"Liu","year":"2001","journal-title":"Oncogene"},{"key":"R16-13-20210203","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/s00280-007-0473-0","article-title":"The gemcitabine, docetaxel and capecitabine (GTX) regimen for metastatic prostate cancer: a retrospective analysis","volume":"61","author":"Fine","year":"2008","journal-title":"Cancer Chemother Pharmacol"},{"key":"R17-13-20210203","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1056\/NEJMoa0804385","article-title":"K-ras mutations and benefit from cetuximab in advanced colorectal cancer","volume":"359","author":"Karpetis","year":"2008","journal-title":"N Engl J Med"},{"key":"R18-13-20210203","doi-asserted-by":"crossref","first-page":"4524","DOI":"10.1200\/JCO.2005.19.711","article-title":"Molecular markers of early pancreatic cancer","volume":"23","author":"Goggins","year":"2005","journal-title":"J Clin Oncol"},{"key":"R19-13-20210203","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1634\/theoncologist.8-2-149","article-title":"The medical management of pancreatic cancer: a review","volume":"8","author":"McKenna","year":"2003","journal-title":"Oncologist"},{"key":"R20-13-20210203","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1093\/annonc\/mdn063","article-title":"Pancreatic cancer is the wall crumbling?","volume":"19","author":"Chua","year":"2008","journal-title":"Ann Oncol"},{"key":"R21-13-20210203","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1002\/1096-9098(200008)74:4<243::AID-JSO1>3.0.CO;2-C","article-title":"Can we screen high risk individuals to detect early pancreatic carcinoma?","volume":"74","author":"Goggins","year":"2000","journal-title":"J Surg Oncol"},{"key":"R22-13-20210203","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1200\/JCO.2006.09.2452","article-title":"Panc PRO: risk assessment for individuals with a family history of pancreatic cancer","volume":"25","author":"Wang","year":"2007","journal-title":"J Clin Oncol"},{"key":"R23-13-20210203","first-page":"5360","article-title":"Germline BRCA2 gene mutations in patients with apparently sporadic pancreatic carcinomas","volume":"56","author":"Goggins","year":"1996","journal-title":"Cancer Res"},{"key":"R24-13-20210203","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1093\/jnci\/91.15.1310","article-title":"Cancer risks in BRCA2 carriers","volume":"91","year":"1999","journal-title":"J Natl Cancer Inst"},{"key":"R25-13-20210203","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1093\/jnci\/95.3.214","article-title":"BRCA2 germline mutations in familial pancreatic carcinoma","volume":"95","author":"Hahn","year":"2003","journal-title":"J Natl Cancer Inst"},{"key":"R26-13-20210203","doi-asserted-by":"crossref","first-page":"3396","DOI":"10.1200\/JCO.1999.17.11.3396","article-title":"Survival in hereditary breast cancer associated with germline mutations of BRCA2","volume":"17","author":"Verhoog","year":"1999","journal-title":"J Clin Oncol"},{"key":"R27-13-20210203","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1056\/NEJMoa070608","article-title":"Clinical outcomes of breast cancer in carriers of BRCA1 and BRCA2 mutations","volume":"357","author":"Rennert","year":"2007","journal-title":"N Engl J Med"},{"key":"R28-13-20210203","doi-asserted-by":"crossref","first-page":"2719","DOI":"10.1517\/14656566.8.16.2719","article-title":"The role of platinum agents in the management of advanced pancreatic cancer","volume":"8","author":"Saif","year":"2007","journal-title":"Expert Opin Pharmacother"},{"key":"R29-13-20210203","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1186\/1471-2407-8-82","article-title":"Meta-analysis of randomized trials: evaluation of benefit from gemcitabine-based combination chemotherapy applied in advanced pancreatic cancer","volume":"8","author":"Heinemann","year":"2008","journal-title":"BMC Cancer"},{"key":"R30-13-20210203","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1081\/CNV-120000367","article-title":"Randomized phase II study of irinotecan plus mitomycin C vs. oxaliplatin plus mitomycin C in patients with advanced fluoropyrimidine\/leucovorin \u2013 pre-treated colorectal cancer","volume":"20","author":"Scheithauer","year":"2002","journal-title":"Cancer Invest"},{"key":"R31-13-20210203","first-page":"305","article-title":"Response to third line mitomycin C (MMC)-based chemotherapy in a patient with metastatic pancreatic adenocarcinoma carrying germline BRCA2 Mutation","volume":"9","author":"Chalasani","year":"2008","journal-title":"JOP"}],"container-title":["Anti-Cancer Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/CAD.0b013e32832b511e","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T17:49:59Z","timestamp":1786038599000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00001813-200908000-00013"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,8]]},"references-count":31,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2009]]}},"URL":"https:\/\/doi.org\/10.1097\/cad.0b013e32832b511e","relation":{},"ISSN":["0959-4973"],"issn-type":[{"value":"0959-4973","type":"print"}],"subject":[],"published":{"date-parts":[[2009,8]]}}}